Mithra Pharmaceuticals SA
XBRU:MITRA
Mithra Pharmaceuticals SA
Mithra Pharmaceuticals SA operates as a Belgian biotech company, which engages in the development, manufacture, and commercialization of proprietary and differentiated drugs and generic products dedicated to female healthcare. The company is headquartered in Liege, Liege and currently employs 248 full-time employees. The company went IPO on 2015-06-30. The firm is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The firm provides three development candidates built on Mithra’s estrogen platform, Estetrol (E4): Estelle, a solution for oral contraception, PeriNesta, the oral treatment targeting perimenopause and Donesta, a hormone therapy. The firm also develops and manufactures therapeutics in the areas of contraception, menopause and hormone-dependent cancers. The company offers partners a spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. The firm operates in more than 100 countries around the world and is headquartered in Liege, Belgium.
Mithra Pharmaceuticals SA operates as a Belgian biotech company, which engages in the development, manufacture, and commercialization of proprietary and differentiated drugs and generic products dedicated to female healthcare. The company is headquartered in Liege, Liege and currently employs 248 full-time employees. The company went IPO on 2015-06-30. The firm is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The firm provides three development candidates built on Mithra’s estrogen platform, Estetrol (E4): Estelle, a solution for oral contraception, PeriNesta, the oral treatment targeting perimenopause and Donesta, a hormone therapy. The firm also develops and manufactures therapeutics in the areas of contraception, menopause and hormone-dependent cancers. The company offers partners a spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. The firm operates in more than 100 countries around the world and is headquartered in Liege, Belgium.
